ArticleDrug design, development and therapy2026
Comparative Analysis of Progestin Intervention for Non-Atypical Endometrial Hyperplasia in Infertile Females with Anovulation: A Retrospective Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy of progestin intervention for non-atypical endometrial hyperplasia (non-atypical EH) in infertile patients with ovulatory dysfunction, and to explore factors associated with histological regression. Methods: A retrospective cohort study was conducted at a tertiary reproductive medicine center. A total of 171 infertile females with anovulation diagnosed with non-atypical EH by hysteroscopic biopsy between March 2021 and August 2024 were enrolled. Patients were divided into polycystic ovary syndrome (PCOS) group (n=89) and diminished ovarian reserve (DOR) group (n=82) according to ovarian reserve function. All patients received 3-month oral progestin therapy. The study aims to analyze and compare the regression of endometrial hyperplasia after 3 months of treatment. Multivariate logistic regression was used to analyze independent factors affecting treatment response. Results: After progestin treatment, the overall EH regression rate was 82.46%, with no significant difference between the DOR group (84.15%) and PCOS group (80.90%) (P=0.577). In the DOR subgroup, high-potency progestins achieved a significantly higher regression rate than dydrogesterone (89.83% vs 69.57%, P=0.040), while no such difference was found in the PCOS group (P=0.527). The clinical pregnancy rate (31.71% vs 48.31%, P=0.027) and live birth rate (14.63% vs 38.20%, P<0.001) were significantly lower in the DOR group. But no significant association was observed between progestin type and clinical pregnancy (P = 0.097, OR = 0.586, 95% CI 0.312-1.101).Multivariate analysis revealed that lower body mass index (BMI) (OR=0.893, 95% CI: 0.809-0.985, P=0.024) and high-potency progestin regimen (OR=2.913, 95% CI: 1.147-7.400, P=0.025) were independent protective factors for EH regression. Conclusion: Progestin provides comparable histological regression for non-atypical EH in infertile females with anovulation. A potential benefit of high-potency progestins was observed among patients with DOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.